Connect with us

News

Comment: How industry unity in femtech can be a catalyst for women’s health innovation

Published

on

By Sheena D. Franklin, founder of K’ept Health, a women’s focused heath informatics company.

The femtech industry is at a turning point. What started as a niche sector has evolved into a multi-billion-dollar powerhouse addressing critical gaps in women’s health. Yet, despite this rapid growth, femtech founders still face major roadblocks—limited investment, regulatory hurdles, and the lack of comprehensive data needed to drive real change.

For femtech to truly transform women’s health and establish itself as an essential pillar of healthcare innovation, we need to move beyond working in isolation. A more connected, collaborative ecosystem will help shift the perception of femtech from a specialized market to a driving force behind broader healthcare reform.

Breaking silos to build a stronger femtech ecosystem

One of the biggest challenges in femtech today is fragmentation. Companies are making incredible strides in fertility, menopause, chronic disease management, and more—but often in isolation. Without deeper collaboration, we risk redundancy—tackling the same problems separately instead of driving collective progress.

This isn’t just an obstacle—it’s a missed opportunity. Too many femtech founders navigate regulatory hurdles, consumer trust issues, and market education barriers alone, without tapping into the collective knowledge of their peers. The truth is, no single company can solve all the unmet needs in women’s health on its own. But by sharing insights, resources, and lessons learned, founders can accelerate progress—not just for their own companies, but for the entire industry.

Other sectors have successfully made this shift. Fintech, for example, has thrived by forming alliances to drive financial inclusion. Femtech can take a similar approach by fostering open dialogue, creating strategic partnerships, and embracing collaboration as a growth strategy. When femtech companies support one another, the industry moves faster, innovation happens more efficiently, and—most importantly—women get better solutions, sooner.

The power of data collaboration to overcome silos

Breaking down silos is one thing—but real progress happens when companies collaborate on data. Many femtech companies collect valuable user-generated health data, yet without a secure way to share and analyse these insights, the industry misses a huge opportunity to drive systemic change.

Understandably, concerns over competitive advantage and patient trust make data-sharing a tricky subject. But companies that find responsible, privacy-focused ways to collaborate on data will lead the next wave of women’s health innovation.

A prime example is the FemIndex by K’ept Health, which is pioneering responsible data collaboration in women’s health. Using federated machine learning, the FemIndex allows secure data sharing across multiple femtech sectors while protecting user privacy. Instead of working in silos, companies can contribute to and benefit from a diverse, high-quality dataset that strengthens AI models, accelerates drug discovery and improves precision medicine.

Industry-wide collaboration is also taking shape through initiatives like The Wonder Woman Collective, which unites femtech companies to streamline specialty care, close coverage gaps, and reduce costs for conditions like migraines, hypothyroidism, and PCOS. This collective is also working to engage payers, conduct cost-saving studies, and advocate for increased federal investment in women’s health. As part of the initiative, participating companies will share anonymized medical records to support R&D efforts.

By combining specialised care platforms with advanced data-sharing infrastructures, we can create a network-driven approach that strengthens femtech’s ability to scale while accelerating progress across the entire industry.

Strength in numbers: Industry standards, policy, and investment

Beyond technology and data, a united femtech sector can wield more influence in shaping policy, investment trends, and regulatory frameworks.

Setting industry standards is key to solidifying femtech as a major force in healthcare. By defining best practices for women’s health technologies, femtech leaders can ensure innovations are safe, effective, and widely trusted. Standardized guidelines also make it easier to secure regulatory approval, attract investors, and drive adoption.

A unified femtech industry can also push for better reimbursement models, clear clinical validation pathways, and stronger partnerships with healthcare providers. Working together, femtech leaders can advocate for insurance coverage that makes solutions more affordable and accessible. Deeper collaboration with hospitals and health systems will drive mainstream adoption and bridge the gaps in traditional care models—positioning femtech as an integral part of modern healthcare.

A united femtech future

Other industries have shown that competitors can work together to drive collective success. In the automotive sector, manufacturers collaborate on safety standards and emissions regulations, raising industry-wide standards while still competing in the market. In pharma, companies share research data to accelerate drug discovery, recognizing that advancing healthcare benefits everyone.

Femtech must do the same. The question is no longer whether should we work together—it’s how quickly we can embrace this shift. The future of femtech depends on our willingness to share knowledge, advocate collectively, and build a unified front that cements femtech as a critical part of the healthcare landscape.

Now is the time to move forward—together.

Sheena D. Franklin is founder of K’ept Health, a women’s focused heath informatics company. He other roles include chair of the Women’s Health Working Group for the Consumer Technology Association, where she leads standards creation for women’s health technology, and a trusted advisor to the American Medical Association and the Aspen Institute. 

Diagnosis

Lung cancer drug shows breast cancer potential

Published

on

Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.

PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.

Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.

The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.

In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.

Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.

Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.

Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”

John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”

Continue Reading

Insight

Higher nighttime temps linked to increased risk of autism diagnosis in children – study

Published

on

Nighttime temperatures during pregnancy may be linked to a higher chance of an autism diagnosis in children, a recent study suggests.

The research tracked nearly 295,000 mother-child pairs in Southern California from 2001 to 2014 and linked warmer overnight temperatures with higher risk in early and late pregnancy.

Children of mothers exposed to higher than typical nighttime temperatures during weeks one to 10 of pregnancy had a 15 per cent higher risk of an autism diagnosis.

Exposure during weeks 30 to 37 was linked to a 13 per cent higher risk.

 Lead author David Luglio, a post-doctoral fellow at Tulane University, said: “A key takeaway is that we identified specific windows when a mother and her developing child can be most affected by exposures to higher nighttime temperatures.

“This is critical and hopefully can help mothers prepare accordingly.”

The study is described as the first to examine how temperature may affect fetal neurodevelopment, the process by which a baby’s brain and nervous system form during pregnancy.

Extreme temperatures linked to increased risk were classified as above the 90th percentile, meaning 3.6°F hotter than average, and the 99th percentile, 5.6°F above average.

The association held even after researchers accounted for factors such as neighbourhood conditions, vegetation and fine-particle air pollution.

The study could not account for other factors such as access to air conditioning. Researchers did not find the same association with daytime temperatures, potentially because people spend more time away from home during the day.

“Heat waves are becoming more frequent, and people may only think of the dangers of daytime heat exposure,” said Mostafijur Rahman, assistant professor of environmental health sciences at Tulane University.

“These results indicate a strong association between high nighttime temperatures during pregnancy and autism risk in children and show that we need to think about exposure to heat around the clock.”

The study did not examine how higher temperatures at night might affect prenatal development, though Luglio said it is possible that warmer nights disrupt sleep for pregnant mothers.

Previous research has suggested insufficient sleep during pregnancy may be linked to a higher risk of neurocognitive delays in children.

“Extreme heat exposure during pregnancy has been linked to a range of adverse health outcomes, including prenatal neurodevelopment delays and complications with an embryo’s development of a central nervous system,” Luglio said.

“The goal of our study was to specifically explore the link between prenatal heat exposure and autism diagnoses for the first time.”

Continue Reading

Entrepreneur

Kindbody unveils next-gen fertility platform

Published

on

Kindbody has launched a fertility platform integrating AI with clinical care and patient support for employers and health plans.

The platform will enter a pilot with select Kindbody employer clients in 2026, covering over three million lives, ahead of wider availability in 2027.

Building on the company’s clinical model, the platform aims to improve outcomes and cost efficiency across family-building journeys. It connects Kindbody-owned clinics, partner clinics and an integrated clinical app.

The app offers virtual care across conception, pregnancy and reproductive health, extending through the menopause transition.

Launch features include updates in medication management, third-party reproduction, adoption, pregnancy, men’s health and global programme design.

David Stern, chief executive of Kindbody, said: “With our next-generation fertility platform, Kindbody is redefining what comprehensive, intelligent and affordable family-building care looks like for employers, health plans and patients.

“By unifying best-in-class clinical care, AI-driven intelligence and whole-person support, we are making it easier and more cost-effective for more people to build the families they envision.”

Kindbody has expanded access via its national network of IVF centres, including IVIRMA, Inception Fertility and Ivy Fertility.

A new Fertility Medication Portal is designed to streamline authorisations so medicines can be dispensed on time, giving patients visibility from prescription to coverage, pharmacy fulfilment and delivery tracking.

Through KindMan, men’s health education, digital resources and integrated clinical care are expanding, including hormone management programmes.

Services cover andropause (age-related testosterone decline), erectile dysfunction, low testosterone and other male reproductive conditions.

Specialist fertility care includes semen analysis, diagnostic testing, male hormone panels, genetic testing, surgical sperm extraction and sperm cryopreservation.

Launching in the second quarter, a pregnancy support app will act as a digital companion for expecting and new parents, with resources, interactive tools and clinical assessments to identify social drivers of health and mental health needs during pregnancy and beyond.

Kindbody’s physician-led menopause programme provides consultations with board-certified obstetricians and gynaecologists to diagnose, treat and manage menopausal symptoms, including hormone replacement therapy where appropriate, with support from nutritionists, mental health therapists and pelvic floor specialists.

AI and analytics will be embedded across the care journey. An AI care navigator will guide employees from benefit activation through intake, triage and scheduling.

Tools will track benefits and treatment plans, showing coverage and expected out-of-pocket costs at each step.

AI-supported scribing will assist clinicians with documentation, and a predictor tool will estimate a patient’s likelihood of having a baby across different treatment paths.

In 2027, Kindbody plans a savings model for eligible large employers that it says will guarantee lower total fertility spend while improving clinical efficiency and patient experience.

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.